The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Open accessAbstract
Acetyl coenzyme A (AcCoA) is the central biosynthetic precursor for fatty-acid synthesis and protein acetylation. In the conventional view of mammalian cell metabolism, AcCoA is primarily generated from glucose-derived pyruvate through the citrate shuttle and ATP citrate lyase in the cytosol. However, proliferating cells that exhibit aerobic glycolysis and those exposed to hypoxia convert glucose to lactate at near-stoichiometric levels, directing glucose carbon away from the tricarboxylic acid cycle and fatty-acid synthesis. Although glutamine is consumed at levels exceeding that required for nitrogen biosynthesis, the regulation and use of glutamine metabolism in hypoxic cells is not well understood. Here we show that human cells use reductive metabolism of α-ketoglutarate to synthesize AcCoA for lipid synthesis. This isocitrate dehydrogenase-1 (IDH1)-dependent pathway is active in most cell lines under normal culture conditions, but cells grown under hypoxia rely almost exclusively on the reductive carboxylation of glutamine-derived α-ketoglutarate for de novo lipogenesis. Furthermore, renal cell lines deficient in the von Hippel-Lindau tumour suppressor protein preferentially use reductive glutamine metabolism for lipid biosynthesis even at normal oxygen levels. These results identify a critical role for oxygen in regulating carbon use to produce AcCoA and support lipid synthesis in mammalian cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both HIF-1α and HIF-2α activation promotes the upregulation of the glutamine transporter, SLC38A2, which increases the dependency of cells to glutamine and correlates with poorer survival in patients with breast cancer [58]”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [58]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, checkpoint kinase 1 (CHK1) inhibitors625–627 and glutaminase (GLS) inhibitors628–634 are also considered potential candidates for treating Myc-overexpressing cancers.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [631]
In the citing paper
“Citrate, generated by reductive carboxylation of α-KG, is especially crucial for lipid synthesis under low-oxygen conditions24,25.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [24]
In the citing paper
“and switch the fate of glutamine from the oxidative pathway into the reductive carboxylation pathway24.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [24]
In the citing paper
“In the context of constitutive HIF-2α stabilization75 or a defective mitochondrial electron transport chain76, glutamine-derived α-KG is reductively carboxylated through the consumption of NADPH by IDH2 to generate citrate.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [75]
In the citing paper
“Glutamine acts as an alternative fuel for fatty acid synthesis, supplying citrate via mitochondrial reductive carboxylation, especially under hypoxic conditions74,75.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [75]
In the citing paper
“Alternatively, proliferating cells under hypoxia have been reported to predominantly reductively carboxylate glutamine generated α-ketoglutarate through IDH 1/2 to generate M5 citrate (Figure 4A) (Metallo, 2012).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Metallo, 2012
In the citing paper
“Previous reports showed that reductive carboxylation is a critical pathway to support the growth of tumor cells under hypoxia (Metallo, 2012; Mullen, 2012).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Metallo, 2012
In the citing paper
“The upregulation of the reductive carboxylation pathway enhances cancer cells proliferation (Metallo, 2012; Mullen, 2012; Wise et al., 2011).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Metallo, 2012
In the citing paper
“For example, under conditions of hypoxia or impaired mitochondrial respiration, certain reactions of the TCA cycle reverse to support glutamine-dependent reductive carboxylation (92, 122, 123).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [122]
In the citing paper
“In a process referred to as reductive carboxylation, a section of the TCA cycle reverses itself, converting α-ketoglutarate into citrate, which can be then used to generate a source of cytosolic acetyl-CoA (Metallo et al., 2012; Wise et al., 2011).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Metallo et al., 2012
In the citing paper
“Citrate is generated by citrate synthase (CS) or through the reduction of α-ketoglutarate by isocitrate dehydrogenase (IDH).79–81”
From The multifaceted contributions of mitochondria to cellular metabolism (2018) · cites this paper as [79]
In the citing paper
“Citrate levels, however, were markedly decreased in Mpc1KD or Mpc2KD (Mpc1/2KD) cells, as this metabolite is generated predominantly from pyruvate-derived AcCoA under normal growth conditions (Metallo et al., 2012).”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Metallo et al., 2012
In the citing paper
“Glutamine can contribute carbon to fatty acid synthesis via reductive carboxylation or oxidative glutaminolysis.”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Metallo et al., 2012
In the citing paper
“The former pathway is highly active in cells proliferating under hypoxia or those with a compromised respiratory chain (Metallo et al., 2012; Mullen et al., 2012; Scott et al., 2011; Wise et al., 2011), while the latter pathway has been observed in B cell lymphoma (Le et al., 2012).”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Metallo et al., 2012
In the citing paper
“This switch to reductive versus oxidative metabolism of α-KG is regulated in part by HIF-1α (71, 72), although the exact mechanism by which HIF-1α does so remains unclear.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [71]
In the citing paper
“Although oxidation of glutamine-derived α-KG in the TCA cycle serves as a minor source of lipogenic acetyl-CoA under normal growth conditions, α-KG can be converted to citrate through reductive carboxylation under conditions of stress such as hypoxia or mitochondrial dysfunction (70–72).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [71]
In the citing paper
“The work from Metallo and colleagues (71) suggests that T cells can use reductive glutamine metabolism for fatty acid biosynthesis under hypoxic conditions.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [71]
In the citing paper
“In place of oxidative metabolism of both glucose and glutamine, these cancers preferentially perform reductive and carboxylating biosynthetic reactions from glutamine carbon (Le et al., 2012; Metallo et al., 2012; Mullen et al., 2012; Wise et al., 2011).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Metallo et al., 2012
In the citing paper
“Recently three independent reports implicated IDH-dependent reductive carboxylation as playing a particularly important role in proliferating cells that exhibit decreased flux of glucose-derived pyruvate into the mitochondria. This occurs in hypoxic cells or in cells harboring defects in mitochondrial oxidative phosphorylation (Metallo et al., 2012; Mullen et al., 2012; Wise et al., 2011).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Metallo et al., 2012
In the citing paper
“tumor cells with mutations in the TCA cycle or ETC (Mullen et al., 2011), or with hypoxia-induced suppression of oxidative metabolism (Metallo et al., 2011; Scott et al., 2011; Wise et al., 2011) use reductive carboxylation of α-KG to produce citrate and other precursors during growth.”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Metallo et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“The von Hippel–Lindau (VHL) tumour suppressor protein is frequently lost in renal cell carcinoma (RCC) and results in a state of ‘pseudohypoxia’ by activating HIF signallin”
BackgroundKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
ATP-citrate lyase links cellular metabolism to histone acetylation
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1164097 · Cited by 2,298
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Flagged first, then by citations
1 of the 43 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 1,003
Rational Cell Culture Optimization Enhances Experimental Reproducibility in Cancer Cells
Wright Muelas, M., Ortega, F., Breitling, R., Bendtsen, C., & Westerhoff, H. V. (2018) · Scientific Reports · doi:10.1038/s41598-018-21050-4 · Cited by 160
Metabolic consequences of oncogenic IDH mutations
Parker, S. J., & Metallo, C. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.003 · Cited by 162
Self-citationInhibition of the mitochondrial pyruvate carrier protects from excitotoxic neuronal death
Divakaruni, A. S., Wallace, M., Buren, C., Martyniuk, K. M., Andreyev, A. Y., Li, E., Fields, J. A., Cordes, T., Reynolds, I. J., Bloodgood, B. L., et al. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201612067 · Cited by 169
Self-citationThe Distinct Role of HIF-1α and HIF-2α in Hypoxia and Angiogenesis
Bakleh, M. Z., & Zen, A. A. H. (2025) · Cells · doi:10.3390/cells14090673 · Cited by 190
MYC-induced reprogramming of glutamine catabolism supports optimal virus replication
Thai, M., Thaker, S. K., Feng, J., Du, Y., Hu, H., Wu, T., Graeber, T. G., Braas, D., & Christofk, H. R. (2015) · Nature Communications · doi:10.1038/ncomms9873 · Cited by 153
Ren, P., Yue, M., Xiao, D., Xiu, R., Gan, L., Liu, H., & Qing, G. (2014) · The Journal of Pathology · doi:10.1002/path.4429 · Cited by 157
PGC-1α supports glutamine metabolism in breast cancer
McGuirk, S., Gravel, S., Deblois, G., Papadopoli, D. J., Faubert, B., Wegner, A., Hiller, K., Avizonis, D. Z., Akavia, U. D., Jones, R. G., et al. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-22 · Cited by 160
Self-citationGlutamate and α-ketoglutarate: key players in glioma metabolism
Maus, A., & Peters, G. J. (2016) · Amino Acids · doi:10.1007/s00726-016-2342-9 · Cited by 162
Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017) · Cancer · doi:10.1002/cncr.31039 · Cited by 154
Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells
Sunami, Y., Rebelo, A., & Kleeff, J. H. (2017) · Cancers · doi:10.3390/cancers10010003 · Cited by 157
Mitochondrial Metabolism Regulation of T Cell–Mediated Immunity
Steinert, E. M., Vasan, K., & Chandel, N. S. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-082015 · Cited by 161
Therapeutic Strategies Impacting Cancer Cell Glutamine Metabolism
Lukey, M. J., Wilson, K. F., & Cerione, R. A. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.130 · Cited by 155
Teicher, B. A., Linehan, W. M., & Helman, L. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2587 · Cited by 152
Glioblastoma Stem-Like Cells, Metabolic Strategy to Kill a Challenging Target
Garnier, D., Renoult, O., Alves‐Guerra, M., Paris, F., & Pecqueur, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00118 · Cited by 161
The role of hypoxia in pancreatic cancer: a potential therapeutic target?
Erkan, M., Kurtoğlu, M., & Kleeff, J. H. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1117386 · Cited by 157
Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
Zhou, W., & Wahl, D. R. (2019) · Cancers · doi:10.3390/cancers11091231 · Cited by 152
Central roles of apoptotic proteins in mitochondrial function
Kilbride, S. M., & Prehn, J. H. M. (2012) · Oncogene · doi:10.1038/onc.2012.348 · Cited by 150
The redox requirements of proliferating mammalian cells
Hosios, A. M., & Heiden, M. G. V. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.tm117.000239 · Cited by 157
When fats commit crimes: fatty acid metabolism, cancer stemness and therapeutic resistance
Kuo, C., & Ann, D. K. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0317-9 · Cited by 153
Redox control of glutamine utilization in cancer
Alberghina, L., & Gaglio, D. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.513 · Cited by 150
Reductive TCA cycle metabolism fuels glutamine- and glucose-stimulated insulin secretion
Zhang, G., Jensen, M. V., Gray, S. M., EL, K. M., Wang, Y., Lu, D., Becker, T. C., Campbell, J. E., & Newgard, C. B. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.020 · Cited by 153
Hypoxia-inducible factors: Crosstalk between inflammation and metabolism
Shay, J. E. S., & Simon, M. C. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.04.004 · Cited by 146
Cancer’s Fuel Choice: New Flavors for a Picky Eater
DeNicola, G. M., & Cantley, L. C. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.018 · Cited by 149
António, C., Päpke, C., Rocha, M., Diab, H., Limami, A. M., Obata, T., Fernie, A. R., & van Dongen, J. T. (2015) · PLANT PHYSIOLOGY · doi:10.1104/pp.15.00266 · Cited by 145
The Metabolic Fates of Pyruvate in Normal and Neoplastic Cells
Prochownik, E. V., & Wang, H. (2021) · Cells · doi:10.3390/cells10040762 · Cited by 150
Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies
Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B. (2022) · Cancers · doi:10.3390/cancers14194568 · Cited by 144
Makris, E. A., Responte, D. J., Paschos, N. K., Hu, J. C. Y., & Athanasiou, K. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414271111 · Cited by 144
Chinopoulos, C. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23196 · Cited by 148
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
Fack, F., Espedal, H., Keunen, O., Golebiewska, A., Obad, N., Harter, P. N., Mittelbronn, M. G. A., Bähr, O., Weyerbrock, A., Stuhr, L. E. B., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1352-5 · Cited by 146
Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization
Björnson, E., Mukhopadhyay, B., Asplund, A., Pristovšek, N., Çınar, R., Romeo, S., Uhlén, M., Kunos, G., Nielsen, J., & Mardinoğlu, A. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.045 · Cited by 142
Mitochondrial complex I promotes kidney cancer metastasis
Bezwada, D., Perelli, L., Lesner, N. P., Cai, L., Brooks, B., Wu, Z., Vu, H., Sondhi, V., Cassidy, D. L., Kasitinon, S. Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07812-3 · Cited by 158
Exogenous Fatty Acids Are the Preferred Source of Membrane Lipids in Proliferating Fibroblasts
Yao, C.-H., Fowle-Grider, R., Mahieu, N. G., Liu, G., Chen, Y., Wang, R., Singh, M., Potter, G. S., Gross, R. W., Schaefer, J., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.03.007 · Cited by 142
The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy
Lai, Y., Tang, F., Huang, Y., He, C., Chen, C., Zhao, J., Wu, W., & He, Z. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29969 · Cited by 140
Perspectives in the treatment of pancreatic adenocarcinoma
Arregui, A. C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i31.9297 · Cited by 146
EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection
Olenchock, B. A., Moslehi, J. J., Baik, A. H., Davidson, S. M., Williams, J., Gibson, W. J., Chakraborty, A. A., Pierce, K. A., Miller, C. M., Hanse, E. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.006 · Cited by 145
Sormendi, S., & Wielockx, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00040 · Cited by 147
Libiad, M., Vitvitsky, V., Bostelaar, T., Bak, D. W., Lee, H., Sakamoto, N., Fearon, E. R., Lyssiotis, C. A., Weerapana, E., & Banerjee, R. V. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009442 · Cited by 136
Robey, R. B., Weisz, J., Kuemmerle, N. B., Salzberg, A. C., Berg, A. S., Brown, D. G., Maurer, L. L., Palorini, R., Al‐Mulla, F., Al-Temaimi, R. A., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv037 · Cited by 143
Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment
Justus, C., Sanderlin, E. J., & Yang, L. V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160511055 · Cited by 139
Serine deprivation enhances antineoplastic activity of biguanides
Gravel, S.-P., Hulea, L., Toban, N., Birman, E., Blouin, M.-J., Zakikhani, M., Zhao, Y., Topisirovic, I., St-Pierre, J., & Pollak, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2643-t · Cited by 138
Bioinformatics: The Next Frontier of Metabolomics
Johnson, C. H., Ivanišević, J., Benton, H. P., & Siuzdak, G. E. (2014) · Analytical Chemistry · doi:10.1021/ac5040693 · Cited by 140
Klasson, T. D., LaGory, E. L., Zhao, H., Huynh, S. K., Papandreou, I., Moon, E. J., & Giaccia, A. J. (2022) · Cancer & Metabolism · doi:10.1186/s40170-022-00290-z · Cited by 145
Obre, E., & Rossignol, R. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.12.008 · Cited by 137
Effects of hypoxia and HIFs on cancer metabolism
Mucaj, V., Shay, J. E. S., & Simon, M. C. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1070-5 · Cited by 137
mTORC2 in the center of cancer metabolic reprogramming
Masui, K., Cavenee, W. K., & Mischel, P. S. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.04.002 · Cited by 140
Metabolic flux rewiring in mammalian cell cultures
Young, J. D. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.04.016 · Cited by 144
Metabolic requirements for cancer cell proliferation
Keibler, M. A., Wasylenko, T. M., Kelleher, J. K., Iliopoulos, O., Heiden, M. G. V., & Stephanopoulos, G. N. (2016) · Cancer & Metabolism · doi:10.1186/s40170-016-0156-6 · Cited by 141
Self-citationTumour microenvironment factors shaping the cancer metabolism landscape
Anastasiou, D. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.412 · Cited by 138
Quantitative Sub-Cellular Acyl-Coa Analysis Reveals Distinct Nuclear Regulation
Trefely, S., Huber, K., Liu, J., Noji, M., Stransky, S., Singh, J. P., Doan, M. T., Lovell, C. D., von Krusenstiern, E. V., Jiang, H., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.006 · Cited by 139
Lipid Metabolism at the Nexus of Diet and Tumor Microenvironment
Peck, B., & Schulze, A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.007 · Cited by 138
2-Hydroxyglutarate in Cancer Cells
Ježek, P. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130
Hopefully devoted to Q: targeting glutamine addiction in cancer
Still, E. R., & Yuneva, M. O. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.113 · Cited by 142
Lipid Deprivation Induces a Stable, Naive-to-Primed Intermediate State of Pluripotency in Human PSCs
Cornacchia, D., Zhang, C., Zimmer, B., Chung, S. Y., Fan, Y., Soliman, M. A., Tchieu, J. H., Chambers, S. M., Shah, H., Paull, D. J., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.05.001 · Cited by 131
Metabolic Fitness and Plasticity in Cancer Progression
McGuirk, S., Audet-Delage, Y., & St‐Pierre, J. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.11.009 · Cited by 133
Zhu, H., Zou, G., Wang, N., Zhuang, M., Xiong, W., & Huang, G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615557114 · Cited by 133
Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance
Belisario, D. C., Kopecka, J., Pasino, M., Akman, M., De Smaele, E., Donadelli, M., & Riganti, C. (2020) · Cells · doi:10.3390/cells9122598 · Cited by 133
The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation
Yan, M., Gingras, M., Dunlop, E. A., Nouët, Y., Dupuy, F., Jalali, Z., Possik, E., Coull, B. J., Kharitidi, D., Dydensborg, A. B., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71749 · Cited by 141
Scotland, S., Saland, E., Skuli, N., de Toni, F., Boutzen, H., Micklow, E., Sénégas, I., Peyraud, R., Peyriga, L., Théodoro, F., et al. (2013) · Leukemia · doi:10.1038/leu.2013.107 · Cited by 149
Short overview on metabolomics approach to study pathophysiology of oxidative stress in cancer
Andrišić, L., Dudzik, D., Barbas, C., Milković, L., Grune, T., & Žarković, N. (2017) · Redox Biology · doi:10.1016/j.redox.2017.08.009 · Cited by 137
Regulation of branched-chain amino acid metabolism by hypoxia-inducible factor in glioblastoma
Zhang, B., Chen, Y., Shi, X., Zhou, M., Bao, L., Hatanpaa, K. J., Patel, T., DeBerardinis, R. J., Wang, Y., & Luo, W. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03483-1 · Cited by 126
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism
Encarnación-Rosado, J., Sohn, A. S. W., Biancur, D. E., Lin, E. Y., Osorio-Vasquez, V., Rodrick, T. C., González-Baerga, D., Zhao, E., Yokoyama, Y., Simeone, D. M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00647-3 · Cited by 138
Alternative fuels for cancer cells
Keenan, M. M., & Chi, J.-T. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000104 · Cited by 131
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer
Morotti, M., Bridges, E., Valli, A., Choudhry, H., Sheldon, H., Wigfield, S., Gray, N., Zois, C. E., Grimm, F., Jones, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818521116 · Cited by 131
Metabolic regulation by SIRT3: implications for tumorigenesis
Finley, L. W. S., & Haigis, M. C. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.05.004 · Cited by 134
Metabolic Reprogramming in Brain Tumors
Venneti, S., & Thompson, C. B. (2017) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044329 · Cited by 139
Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer
Hutton, J. E., Wang, X., Zimmerman, L. J., Slebos, R. J. C., Trenary, I. A., Young, J. D., Li, M., & Liebler, D. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058925 · Cited by 139
Gammage, P. A., Gaude, E., Haute, L. V., Rebelo‐Guiomar, P., Jackson, C. B., Rorbach, J., Pękalski, M. Ł., Robinson, A. J., Charpentier, M., Concordet, J., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw676 · Cited by 143
The α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity
Vatrinet, R., Leone, G., Luise, M. D., Girolimetti, G., Vidone, M., Gasparre, G., & Porcelli, A. M. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0165-0 · Cited by 133
Global Profiling Strategies for Mapping Dysregulated Metabolic Pathways in Cancer
Benjamin, D. I., Cravatt, B. F., & Nomura, D. K. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.013 · Cited by 131
Collagen Matrix Density Drives the Metabolic Shift in Breast Cancer Cells
Morris, B., Burkel, B. M., Ponik, S. M., Fan, J., Condeelis, J. S., Aguirre‐Ghiso, J. A., Castracane, J., Denu, J. M., & Keely, P. J. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.012 · Cited by 128
Glutamine Addiction and Therapeutic Strategies in Lung Cancer
Vanhove, K., Derveaux, E., Graulus, G., Mesotten, L., Thomeer, M., Noben, J., Guedens, W., & Adriaensens, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020252 · Cited by 135
Suburu, J., & Chen, Y. Q. (2012) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2012.03.003 · Cited by 134
Kang, Y., Tiziani, S., Park, G., Kaul, M., & Paternostro, G. (2014) · Nature Communications · doi:10.1038/ncomms4672 · Cited by 129
Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death
Catanzaro, D., Gaude, E., Orso, G., Giordano, C., Guzzo, G., Rasola, A., Ragazzi, E., Caparrotta, L., Frezza, C., & Montopoli, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4945 · Cited by 126
Amplification of USP13 drives ovarian cancer metabolism
Han, C., Yang, L., Choi, H. H., Baddour, J., Achreja, A., Liu, Y., Li, Y., Li, J., Wan, G., Huang, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms13525 · Cited by 127
Serine catabolism generates liver NADPH and supports hepatic lipogenesis
Zhang, Z., TeSlaa, T. A., Xu, X., Zeng, X., Yang, L., Xing, G., Tesz, G. J., Clasquin, M. F., & Rabinowitz, J. D. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00487-4 · Cited by 130
Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
Al‐Khallaf, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0165-3 · Cited by 133
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
Cho, Y. S., Levell, J. R., Liu, G., Caferro, T. R., Sutton, J. C., Shafer, C. M., Costales, A., Manning, J. R., Zhao, Q. L., Sendzik, M., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00342 · Cited by 125
Gameiro, P. A., Laviolette, L. A., Kelleher, J. K., Iliopoulos, O., & Stephanopoulos, G. N. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.396796 · Cited by 126
Self-citationWoolf, E. C., Syed, N., & Scheck, A. C. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00122 · Cited by 126
Matias, M. I., Yong, C. S. M., Foroushani, A. B. K., Goldsmith, C., Mongellaz, C., Sezgin, E., Levental, K. R., Talebi, A., Perrault, J., Riviere, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109911 · Cited by 124
Functional Assessment of Lipoyltransferase-1 Deficiency in Cells, Mice, and Humans
Ni, M., Solmonson, A., Pan, C., Yang, C., Li, D., Notzon, A., Cai, L., Guevara, G., Zacharias, L. G., Faubert, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.005 · Cited by 124
The complex landscape of pancreatic cancer metabolism
Sousa, C. M., & Kimmelman, A. C. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu097 · Cited by 125
AGC1/2, the mitochondrial aspartate-glutamate carriers
Amoêdo, N. D., Punzi, G., Obre, É., Lacombe, D., Grassi, A., Pierri, C. L., & Rossignol, R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.04.011 · Cited by 128
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
Cervantes-Madrid, D., Romero, Y., & Dueñas‐González, A. (2015) · BioMed Research International · doi:10.1155/2015/690492 · Cited by 125
Niche-Selective Inhibition of Pathogenic Th17 Cells by Targeting Metabolic Redundancy
Wu, L., Hollinshead, K. E. R., Hao, Y., Au, C., Kroehling, L., Ng, C., Lin, W.-Y., Li, D., Silva, H. M., Shin, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.014 · Cited by 119
Non-invasive metabolic imaging of brain tumours in the era of precision medicine
Kim, M. M., Parolia, A., Dunphy, M. P., & Venneti, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.108 · Cited by 121
Lipid Metabolism and Resistance to Anticancer Treatment
Germain, N., Dhayer, M., Boileau, M., Fovez, Q., Kluza, J., & Marchetti, P. (2020) · Biology · doi:10.3390/biology9120474 · Cited by 115
Zaidi, N., Royaux, I. E., Swinnen, J. V., & Smans, K. A. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0095 · Cited by 118
Zhang, H., Badur, M. G., Divakaruni, A. S., Parker, S. J., Jäger, C., Hiller, K., Murphy, A. N., & Metallo, C. M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.102 · Cited by 118
Self-citationZarei, M., Lal, S., Parker, S. J., Nevler, A., Gohar, A. V., Dukleska, K., Mambelli-Lisboa, N. C., Moffat, C., Blanco, F. F., Chand, S. N., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0015 · Cited by 119
Self-citationMetabolic Regulation of Redox Balance in Cancer
Purohit, V., Simeone, D. M., & Lyssiotis, C. A. (2019) · Cancers · doi:10.3390/cancers11070955 · Cited by 121
Signaling, metabolism, and cancer: An important relationship for therapeutic intervention
Vaghari‐Tabari, M., Ferns, G. A., Qujeq, D., Andevari, A. N., Sabahi, Z., & Moein, S. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30276 · Cited by 126
Hollinshead, K. E. R., Parker, S. J., Eapen, V. V., Encarnación-Rosado, J., Sohn, A. S. W., Oncu, T., Cammer, M., Mancias, J. D., & Kimmelman, A. C. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108231 · Cited by 118
Metabostemness: A New Cancer Hallmark
Menéndez, J. A., & Alarcón, T. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00262 · Cited by 116
Reductive carboxylation is a major metabolic pathway in the retinal pigment epithelium
Du, J., Yanagida, A., Knight, K., Engel, A. L., Vo, A. H., Jankowski, C. S. R., Sadı́lek, M., Tran, V., Manson, M. A., Ramakrishnan, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604572113 · Cited by 115
Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers
Chappell, J. C., Payne, L. B., & Rathmell, W. K. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120855 · Cited by 117
Okamatsu‐Ogura, Y., Kuroda, M., Tsutsumi, R., Tsubota, A., Saito, M., Kimura, K., & Sakaue, H. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154396 · Cited by 124
Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism
Valcárcel-Jiménez, L., & Frezza, C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02412-w · Cited by 117
Metadata
- Authors
- Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., Kelleher, J. K., Vander Heiden, M. G., Iliopoulos, O., & Stephanopoulos, G.
- Affiliations
- Massachusetts Institute of Technology (US)
- Massachusetts General Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Iliopoulos, Othon
- Stephanopoulos, Gregory
- ORCID
- Venue
- Nature
- Published
- 2011-11-20
- Volume
- 481
- Issue
- 7381
- Pages
- 380-384
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3710581
- OpenAlex
- W2116516144
- Cited by
- 1,791
- References
- 43
- Citations by year
- 2026: 82 · 2025: 95 · 2024: 96 · 2023: 137 · 2022: 156 · 2021: 143 · 2020: 149 · 2019: 125 · 2018: 100 · 2017: 135 · 2016: 129 · 2015: 125 · 2014: 119 · 2013: 112 · 2012: 84
- FWCI
- 34.61
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- RePEc: Research Papers in Economics (submittedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Damon Runyon Cancer Research Foundation
- Wellcome Trust
- Agios Pharmaceuticals
- National Institutes of Health
- National Cancer Institute (R01CA160458, R01CA122591, P30CA014051)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK075850)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- IDH1, lipogenesis, hypoxia, reductive carboxylation, alpha-ketoglutarate, acetyl-CoA, fatty acid synthesis, VHL, renal cell carcinoma, cancer metabolism, mitochondrial dysfunction, aerobic glycolysis
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Acetyl Coenzyme A, Carbon, Carcinoma, Renal Cell, Cells, Cultured, Citric Acid Cycle, Glutamine, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Kidney Neoplasms, Oxidation-Reduction, Oxygen, Cell Hypoxia, CD8-Positive T-Lymphocytes, Palmitic Acid, Cell Line, Tumor, Lipogenesis, Aryl Hydrocarbon Receptor Nuclear Translocator, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
